Evolution of Antibiotic Use and Cost in Patients with Community-Acquired Pneumonia

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.22, Iss.9, 2002-01, pp. : 601-608

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Moxifloxacin cost saving for community-acquired pneumonia

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 554, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Clinical Use of Cefuroxime in Paediatric Community-Acquired Pneumonia

By Olivier C.

Pediatric Drugs, Vol. 2, Iss. 5, 2000-09 ,pp. : 331-343

Adis International

Access to resources Recommend Favorite

Improving Outcomes of Elderly Patients with Community-Acquired Pneumonia

By Gutiérrez Félix Masiá Mar

Drugs & Aging, Vol. 25, Iss. 7, 2008-01 ,pp. : 585-610

Adis International

Access to resources Recommend Favorite

Does Antibiotic Choice Affect Length of Stay for Community‐Acquired Pneumonia?

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 35, Iss. 1, 2005-03 ,pp. : 25-27

John Wiley & Sons Inc

Access to resources Recommend Favorite

Resource Use and Cost of Care for Patients Hospitalised with Community Acquired Pneumonia: Impact of Adherence to Infectious Diseases Society of America Guidelines

By Joanne J. Orrick

PharmacoEconomics, Vol. 22, Iss. 11, 2004-01 ,pp. : 751-757

Adis International

Access to resources Recommend Favorite